ASC63 / Ascletis - LARVOL DELTA

In vivo antitumor efficacy evaluation of ASC63, an oral small molecule PD-L1 inhibitor, in a humanized mouse tumor model (AACR 2023) - "Results of this study show that ASC63 is in general well tolerated in CT26-hPD−L1 humanized mouse tumor model, and ASC63 has comparable antitumor efficacy as the FDA-approved PD-L1 antibody, Atezolizumab. ASC63 is an oral small molecule PD-L1 inhibitor, and thus will have better patient compliance than injective PD-1/PD-L1 antibody. Results of this study support the continued investigation of ASC63."

Preclinical • Oncology